GLP-1 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-30. Anything still debated is marked as such rather than presented as settled.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
=== Manufacturer === The company the makes Cetacaine is called Cetylite Industries, Inc. This company is based out of Pennsauken, NJ and has a total of 75 employees. Cetylite brings in total revenue of around $7,500,000 with their main product being the topical anesthetics, and infection prevention products.
=== December === 4 December – Michael O'Neill, musician (Screaming Meemees) (born 1963). 6 December Ken Hyde, marketing academic (Auckland University of Technology) (born 1959). Bill Sutton, politician and biochemist (DSIR), MP for Hawkes Bay (1984–1990), Hawke's Bay Regional Councillor (1992–1995) (born 1944). 8 December – Murray Jones, mountaineer (born 1945). 9 December – Ross Morrison, cricketer (Auckland) and tennis administrator (born 1937). 10 December Stuart Davis, horticulturist (born 1959). Bob Manthei, educationist (University of Canterbury) and basketball commentator (born 1946). 11 December – Brent McLachlan, rock drummer (Bailter Space) and music producer (born 1961). 12 December Kelvin Lloyd, ecologist, Loder Cup (2025) (born 1968). Marilyn Yeoman, school principal and community volunteer (Hamilton Gardens), president of the New Zealand Principals' Federation (1995–1997) (born 1942). 13 December – Garry Smith, rugby league player (West Coast, Wellington, national team) (born 1941). 16 December – Alan Marley, association footballer (Dover, New Brighton, national team) (born 1951). 17 December – Peter Arnett, journalist (The Southland Times, Associated Press, CNN), Pulitzer Prize (1966) (born 1934). 21 December – John Lee, businessman and tourism pioneer (Cardrona Alpine Resort, Snow Farm, Southern Hemisphere Proving Grounds) (born 1936). 23 December – Robert Smellie, lawyer and judge, King's Counsel (since 1979), High Court judge (1985–1998) (born 1930).
The book presented her observations from more than 300 experiments over the span of five years, during which she attempted to discover factors necessary for the preservation of beef, eggs, and other foods. Her work was recommended for royal privilege by fellow chemist Pierre-Joseph Macquer. c. 1775: French explorer, herbalist and botanist Jeanne Baret becomes the first woman to circumnavigate the globe. c. 1775: French chemist, scientific artist and translator, Marie-Anne Paulze Lavoisier began working with her husband chemist Antoine Lavoisier. She was instrumental in the 1789 publication of her husband’s groundbreaking Elementary Treatise on Chemistry, which presented a unified view of chemistry as a field, as she drew diagrams of all the equipment used, and kept strict records that lent validity to the findings. She also translated and critiqued Richard Kirwan's 'Essay on Phlogiston and the Constitution of Acids' which led to the discovery of oxygen gas. 1776: At the University of Bologna, Italian physicist Laura Bassi became the first woman appointed as chair of physics at a university. 1776: German astronomer Christine Kirch received a respectable salary of 400 Thaler for calendar-making. See also her sister Margaretha Kirch 1782–1791: French chemist and mineralogist Claudine Picardet translated more than 800 pages of Swedish, German, English and Italian scientific papers into French, enabling French scientists to better discuss and utilize international research in chemistry, mineralogy and astronomy. c.
In all other aspects, however, the RF government perpetuated existing racial segregation and inequalities: the white minority's economic domination and ownership of land was maintained, as was the racial segregation of public services, education and electoral rolls through the party's policy of "separate economic advancement". In contrast to the National Party, whose rule expanded and escalated white domination, the RF sought mainly, with some notable exceptions, to maintain minority rule through inexplicit means. Before the RF's rise to power, separate 'A' and 'B' electoral rolls based on differing income and property qualifications had already de facto disenfranchised the black electorate for decades, with the larger 'A' roll mainly consisting of the wealthier white minority, and the smaller 'B' roll almost exclusively consisting of the small number of Africans eligible and willing to register. Combined with a largely successful boycott campaign from the black majority, this resulted in de facto white minority rule. In an exception to their usual policies, the 1969 constitutional reform explicitly delineated the two electoral rolls by race: With the European 'A' roll increased to 50 seats as opposed to the African 'B' roll only having 8 (with an additional 8 indirectly elected to represent chiefs and tribal interests), this resulted in 270,000 whites having 50 seats and 6 million Africans having 16 seats in the Assembly. These reforms only served to reinforce black rejection of the system.
Sources: en.wikipedia.org
Venom evolved just once among all Toxicofera about 170 million years ago, and then diversified into the huge venom diversity seen today. The original toxicoferan venom was a very simple set of proteins that were assembled in a pair of glands. Subsequently, this set of proteins evolved independently in the various lineages of toxicoferans, including Serpentes, Anguimorpha, and Iguania. Several snake lineages have since lost the ability to produce venom, often due to a change in diet or a change in predatory tactics. In addition to this, venom strength and composition has changed due to changes in the prey of certain snake species. For example, the venom of the marbled sea snake (Aipysurus eydouxii) became significantly less toxic after the diet of this species changed from fish to strictly fish eggs. The evolution of venom is thought to be responsible for the enormous expansion of snakes across the globe. The mechanism of evolution in most cases has been gene duplication in tissues unrelated to the venom. Pre-existing salivary proteins are the likely ancestors of most venom toxin genes. Expression of the new protein in the venom gland followed duplication. Then proceeded natural selection for adaptive traits following the birth-and-death model, where duplication is followed by functional diversification, resulting in the creation of structurally related proteins that have slightly different functions.
Venom is used as a trophic weapon by many predator species. The coevolution between predators and prey is the driving force of venom resistance, which has evolved multiple times throughout the animal kingdom. The coevolution between venomous predators and venom-resistant prey has been described as a chemical arms race. Predator/prey pairs are expected to coevolve over long periods of time. As the predator capitalizes on susceptible individuals, the surviving individuals are limited to those able to evade predation. Resistance typically increases over time as the predator becomes increasingly unable to subdue resistant prey. The cost of developing venom resistance is high for both predator and prey. The payoff for the cost of physiological resistance is an increased chance of survival for prey, but it allows predators to expand into underutilised trophic niches. The California ground squirrel has varying degrees of resistance to the venom of the Northern Pacific rattlesnake. The resistance involves toxin scavenging and depends on the population. Where rattlesnake populations are denser, squirrel resistance is higher. Rattlesnakes have responded locally by increasing the effectiveness of their venom. The kingsnakes of the Americas are constrictors that prey on many venomous snakes. They have evolved resistance which does not vary with age or exposure. They are immune to the venom of snakes in their immediate environment, like copperheads, cottonmouths, and North American rattlesnakes, but not to the venom of, for example, king cobras or black mambas.
In medicine, the urea-to-creatinine ratio (UCR), known in the United States as BUN-to-creatinine ratio, is the ratio of the blood levels of urea (BUN) (mmol/L) and creatinine (Cr) (μmol/L). BUN only reflects the nitrogen content of urea (MW 28), while urea measurement reflects the whole of the molecule (MW 60); urea is just over twice BUN (60/28 = 2.14). In the United States, both quantities are given in mg/dL. The ratio may be used to determine the cause of acute kidney injury or dehydration. The principle behind this ratio is the fact that both urea (BUN) and creatinine are freely filtered by the glomerulus; however, urea reabsorbed by the renal tubules can be regulated (increased or decreased) whereas creatinine reabsorption remains the same (minimal reabsorption).
Sources: en.wikipedia.org
Towards the end of the 16th century, pessaries became more common in the management of uterine prolapse, due in part to advances in anatomic knowledge of the female genitourinary tract earlier in the century. Pessaries were usually made out of wax, metal, glass, or wood. Charles Goodyear's invention of volcanized rubber in the mid-1800s made it possible to produce pessaries that would not decompose. However, even into the 1800s, alternative practices were still used, such as the use of sea-water douches, postural exercises, and leeching. Although the use of surgery in the treatment of uterine prolapse had been described previously, the 19th century saw advances in surgical techniques. During the mid to late 1800s, surgical attempts to manage uterine prolapse included narrowing the vaginal vault, suturing the perineum, and amputating the cervix. In 1877, LeFort described the process of a partial colpocleisis. In 1861, Choppin in New Orleans reported the first instance in which vaginal hysterectomy was performed for uterine prolapse. Prior to that, vaginal hysterectomies were mainly performed for malignancies. Following Alwin Mackenrodt's 1895 publication of a comprehensive description of the female pelvic floor connective tissue, Fothergill began working on the Manchester-Fothergill surgery with the belief that the cardinal and uterosacral ligaments were key support structures for the uterus. In 1907, Josef Haban and Julius Tandler theorized that the levator ani muscles were also very important for uterine support.
Section Alatae Lemna aequinoctialis Welw. – lesser duckweed – tropical and subtropical Lemna perpusilla Torr. – minute duckweed – eastern United States, Quebec Section Biformes Lemna tenera Kurz – Indochina, Sumatra, Northern Territory of Australia Section Lemna Lemna disperma Hegelm. Lemna ecuadoriensis Landolt Lemna gibba L. – gibbous duckweed – widespread Lemna japonica Landolt – Japan, China, Korea, Russian Far East Lemna minor L. – common duckweed – cosmopolitan Lemna obscura (Austin) Daubs – United States, Mexico, Bahamas, Colombia, Ecuador Lemna trisulca L. – ivy duckweed – cosmopolitan Lemna turionifera Landolt – temperate Europe, Asia, North America Section Uninerves Lemna minuta Kunth – least duckweed – North + South America Lemna valdiviana Phil. – Valdivia duckweed – North and South America Lemna yungensis Landolt – Bolivia Formerly placed here Landoltia punctata (G.Mey.) Les & D.J.Crawford (as L. oligorrhiza Kurz and L. punctata G.Mey.) Spirodela polyrhiza (L.) Schleid. (as L. polyrhiza L.) Wolffia arrhiza (L.) Horkel ex Wimm. (as L. arrhiza L.) Wolffia globosa (Roxb.) Hartog & Plas (as L. globosa Roxb.)
== Evolution == The insulin-like growth factor 2 receptor function evolved from the cation-independent mannose 6-phosphate receptor and is first seen in Monotremes. The IGF-2 binding site was likely acquired fortuitously with the generation of an exonic splice site enhancer cluster in exon 34, presumably necessitated by several kilobases of repeat element insertions in the preceding intron. A six-fold affinity maturation then followed during therian evolution, coincident with the onset of imprinting and consistent with the theory of parental conflict.
Works by Marguerite Yourcenar at Open Library Petri Liukkonen. "Marguerite Yourcenar". Books and Writers. Stockinger, Jacob (3 March 2004) [2002]. "Yourcenar, Marguerite (1903–1987)". In Summers, Claude J. (ed.). glbtq: An encyclopedia of gay, lesbian, bisexual, transgender, and queer culture. Chicago: glbtq, Inc. Archived from the original on 16 January 2009. Marguerite Yourcenar et Suzanne Lilar : plus qu’une rencontre, une complicité by Michèle Goslar English translations of Marguerite Yourcenar by Walter Jacob Kaiser, Catalogue of correspondence and manuscripts concerning Walter Kaiser's English translation of works by French writer Marguerite Yourcenar, Houghton Library, Harvard University Accueil
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.